This announcement follows the FDA’s recent agreements on amendments to the Company’s ADI-001 IND application to evaluate three additional indications beyond lupus nephritis (LN), including ...
High levels of integration ensure small solutions size, low component count, and low power consumption. ADI EagleEye™ Intelligence at the edge. Vision Sensing Algorithms for people classification, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback